Xenon Pharmaceuticals Inc (XENE) Dividend History

Xenon Pharmaceuticals Inc. is a biotechnology company focused on developing innovative medicines for neurological and neurological-like disorders. It specializes in using its proprietary platform to identify and develop targeted therapies, with a strong focus on pain, epilepsy, and other neurological conditions. The company employs a deep understanding of ion channels and genetics to advance its pipeline of potential treatments.

200 - 3650 Gilmore Way, Burnaby, A1, V5G 48W
Phone: (604) 484-3300
Website: https://www.xenon-pharma.com

Dividend History

Xenon Pharmaceuticals Inc currently does not pay dividends

Company News

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units. The share options have an exercise price of $38.28 per common share and vest over four years, while the performance share units will vest based on the achievement of certain predefined milestone-based objectives over an approximately three-year period.

GlobeNewswire Inc.
Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight

The epilepsy market is expected to grow due to an increase in disease prevalence and the launch of emerging therapies. The market is segmented into partial epilepsy, chronic focal epilepsy, and drug-resistant epilepsy, with various treatment options and pipeline drugs.

GlobeNewswire Inc.

Featured Companies: OVID
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.

Zacks Investment Research

Featured Companies: ALXO CGEN
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.

GlobeNewswire Inc.
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus

Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Zacks Investment Research

Featured Companies: ANIP ANVS NBIX

Dividend data last updated 06/07/2025 09:49:31 UTC